Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:35 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
NCT04418661 · Sanofi · PHASE1/PHASE2 · terminated · last registry update 2025-05-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor's decision not related to any safety concern” | – | Registry record, Sanofi |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-15Phase 3 first posted: Guangzhou Virotech Pharmaceutical Co., Ltd., VRT106 + VRT106 in combination with camrelizumab and apatinib (NCT07589244)
- 2026-05-11Phase 3 first posted: Pfizer, PF-08634404 + Pembrolizumab (NCT07578649)
- 2026-05-04Phase 3 first posted: Astellas Pharma Global Development, Inc., Enfortumab vedotin + Cisplatin (NCT07566156)
- 2026-04-21Phase 3 first posted: Hoffmann-La Roche, Divarasib + Pembrolizumab (NCT07541170)
- 2026-04-07Phase 3 first posted: Merck Sharp & Dohme LLC, Intismeran + Pembrolizumab coformulated with berahyaluronidase alfa (NCT07513376)
- 2026-03-09Phase 3 first posted: First Affiliated Hospital of Guangxi Medical University, Becotatug Vedotin + Sintilimab (NCT07459296)
- 2026-02-27Results posted on the registry: M.D. Anderson Cancer Center, Lenalidomide + Pembrolizumab (NCT02446457)
- 2026-02-25Phase 3 first posted: Merck Sharp & Dohme LLC, Calderasib + MK-3475A (NCT07431827)
- 2026-01-26Phase 3 first posted: Eikon Therapeutics, EIK1001 + Pembrolizumab (KEYTRUDA®) (NCT07365319)
- 2026-01-23Phase 3 first posted: Bristol-Myers Squibb, Pumitamig + Pembrolizumab (NCT07361510)
- 2026-01-05Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Placebo for pembrolizumab (NCT04221945)
- 2025-12-11Phase 3 first posted: Janssen Research & Development, LLC, Amivantamab + Pembrolizumab (NCT07276399)
- 2025-12-03Results posted on the registry: Merck Sharp & Dohme LLC, Pembrolizumab + Lenvatinib (NCT04704219)
- 2025-11-24Phase 3 first posted: Tianjin Medical University Cancer Institute and Hospital, Toripalimab (NCT07246330)
- 2025-10-23Results posted on the registry: Memorial Sloan Kettering Cancer Center, Pembrolizumab (NCT03728972)
- 2025-10-14Phase 3 first posted: Merck Sharp & Dohme LLC, Pembrolizumab + Sacituzumab Tirumotecan (NCT07216703)
- 2025-10-07Results posted on the registry: UNC Lineberger Comprehensive Cancer Center, Pembrolizumab + Entinostat (NCT03978624)
- 2025-09-30Phase 3 first posted: National Cancer Institute (NCI), Bevacizumab + Carboplatin (NCT07198074)
- 2025-09-29Phase 3 first posted: Boehringer Ingelheim, Zongertinib + Pembrolizumab (NCT07195695)
- 2025-09-24Phase 3 first posted: Merck Sharp & Dohme LLC, Calderasib + Pembrolizumab (+) Berahyaluronidase alfa (NCT07190248)
- 2025-09-09Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., QL2107 + Keytruda® (NCT07162883)
- 2025-07-14Phase 3 first posted: National Cancer Institute (NCI), Carboplatin + Cisplatin (NCT07061977)
- 2025-07-14Phase 3 first posted: Bristol-Myers Squibb, BMS-986504 + Pembrolizumab (NCT07063745)
- 2025-05-29Results posted on the registry: Yuan Yuan, Pembrolizumab + Olaparib (NCT03025035)
- 2025-05-29Results posted on the registry: Diwakar Davar, Pembrolizumab Injection (NCT04808999)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision